Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised TransPerfect in connection with the acquisition of Semantix
Mandate

Vinge advised TransPerfect in connection with the acquisition of Semantix

August 17, 2021 M&A Employment and Benefits

Vinge has advised TransPerfect Global Inc., the world’s leading provider of language and technology solutions for the global market, in connection with the acquisition of Semantix International Group AB, which is the Nordic region’s largest provider of translation and interpreting services.

Semantix has a turnover of approximately MSEK 700 and approximately 320 employees in Sweden, Denmark, Finland, Norway, Spain and Croatia.

Vinge’s team primarily consisted of responsible partner Anders Strid, Anna Jonsson (project manager), Magnus Hedsund, Wilhelm Stenvall, Christian Riddarbo, Emelie Svensäter Jerntorp, Selma Beganovic, Karin Gynnerstadt, Julia Söderdahl, Alexander Lindeberg, Anna Högsten, Gabriella Varga, Jakob Larsson Taghizadeh, Stina Karinsdotter and Erik Ax.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025